ABVC BioPharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Uttam Patil
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | 1.5yrs |
CEO ownership | 0.6% |
Management average tenure | no data |
Board average tenure | 5.8yrs |
Recent management updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05CEO
Uttam Patil (38 yo)
1.5yrs
Tenure
Dr. Uttam Yashwant Patil, Ph D., is Chief Executive Officer of ABVC BioPharma, Inc. from June 21, 2023 and serves as its Interim Chief Financial Officer from July 2024. Dr. Patil has served as the Chief Op...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & Chief Business Officer | 9.4yrs | US$200.00k | 8.16% $ 509.4k | |
Chief Scientific Officer | 5.8yrs | US$200.00k | 3.55% $ 221.6k | |
Director | 7.1yrs | no data | 0.34% $ 21.4k | |
Independent Director | 7.1yrs | no data | 0.34% $ 21.3k | |
Independent Director | 7.1yrs | no data | 0.34% $ 21.4k | |
Independent Director | 5.8yrs | no data | 0.47% $ 29.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Director | 7.1yrs | no data | 0.34% $ 21.3k | |
Independent Director | 2.6yrs | no data | 0.34% $ 21.3k | |
Director | 2.6yrs | no data | 7.12% $ 444.8k | |
Independent Director | 2.5yrs | no data | 0.39% $ 24.5k | |
Independent Director | 2.4yrs | no data | 0.34% $ 21.4k |
5.8yrs
Average Tenure
59yo
Average Age
Experienced Board: ABVC's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 23:49 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jason McCarthy | Maxim Group |
Marla Marin | Zacks Small-Cap Research |